Molecular Imaging of Hypoxia
Open Access
- 3 June 2008
- journal article
- review article
- Published by Society of Nuclear Medicine in Journal of Nuclear Medicine
- Vol. 49 (Suppl 2), 129S-148S
- https://doi.org/10.2967/jnumed.107.045914
Abstract
Hypoxia, a condition of insufficient O2 to support metabolism, occurs when the vascular supply is interrupted, as in stroke or myocardial infarction, or when a tumor outgrows its vascular supply. When otherwise healthy tissues lose their O2 supply acutely, the cells usually die, whereas when cells gradually become hypoxic, they adapt by up-regulating the production of numerous proteins that promote their survival. These proteins slow the rate of growth, switch the mitochondria to glycolysis, stimulate growth of new vasculature, inhibit apoptosis, and promote metastatic spread. The consequence of these changes is that patients with hypoxic tumors invariably experience poor outcome to treatment. This has led the molecular imaging community to develop assays for hypoxia in patients, including regional measurements from O2 electrodes placed under CT guidance, several nuclear medicine approaches with imaging agents that accumulate with an inverse relationship to O2, MRI methods that measure either oxygenation directly or lactate production as a consequence of hypoxia, and optical methods with NIR and bioluminescence. The advantages and disadvantages of these approaches are reviewed, along with the individual strategies for validating different imaging methods. Ultimately the proof of value is in the clinical performance to predict outcome, select an appropriate cohort of patients to benefit from a hypoxia-directed treatment, or plan radiation fields that result in better local control. Hypoxia imaging in support of molecular medicine has become an important success story over the last decade and provides a model and some important lessons for development of new molecular imaging probes or techniques.This publication has 100 references indexed in Scilit:
- In vivo imaging of changes in tumor oxygenation during growth and after treatmentMagnetic Resonance in Medicine, 2007
- Reproducibility of BOLD, perfusion, and CMRO2 measurements with calibrated-BOLD fMRINeuroImage, 2007
- Correlation of radiation response with tumor oxygenation in the Dunning prostate R3327-AT1 tumorInternational Journal of Radiation Oncology*Biology*Physics, 2007
- Imaging oxygenation of human tumoursEuropean Radiology, 2006
- Cell line-dependent differences in uptake and retention of the hypoxia-selective nuclear imaging agent Cu-ATSMNuclear Medicine and Biology, 2005
- Comparison of BOLD contrast and Gd-DTPA dynamic contrast-enhanced imaging in rat prostate tumorMagnetic Resonance in Medicine, 2004
- [18F]Fluoroazomycinarabinofuranoside (18FAZA) and [18F]Fluoromisonidazole (18FMISO): a comparative study of their selective uptake in hypoxic cells and PET imaging in experimental rat tumorsNuclear Medicine and Biology, 2003
- Nitroimidazoles and imaging hypoxiaEuropean Journal of Nuclear Medicine and Molecular Imaging, 1995
- Imaging oxygen tension in liver and spleen by 19F NMRMagnetic Resonance in Medicine, 1993
- Synthesis and biodistribution of 18F-labeled fluoronitroimidazoles: Potential in vivo markers of hypoxic tissueInternational Journal of Radiation Applications and Instrumentation. Part A. Applied Radiation and Isotopes, 1986